Dapagliflozin: Beyond glycemic control in the treatment of type 2 diabetes mellitus

Pol Sanz-Serra, Juan Pedro-Botet, Juana A. Flores-Le Roux, David Benaiges, Juan J. Chillarón

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)


© 2014 Sociedad Española de Arteriosclerosis. Patients with type 2 diabetes mellitus (T2DM) have a high or very high cardiovascular risk. The clinical practice guidelines focus on the need to achieve optimal glycemic control, and strategies for a multifactorial therapeutic approach have shown significant cardiovascular benefits in these patients.Inhibitors of sodium-glucose co-transporter 2 (SGLT-2) are a new class of orally administered drugs in the treatment of T2DM, which act by inhibiting reabsorption of glucose in the renal proximal tubule with consequent glycosuric effect and lowering of blood glucose. Dapagliflozin, SGLT-2 inhibitor marketed in Europe and Australia, has been shown to achieve glycosylated hemoglobin reductions similar to other oral agents, as well as beneficial effects on major comorbidities associated with T2DM. Therefore, it is considered of interest to review the clinical efficacy of this new oral hypoglycemic on glycemic control, risk of hypoglycemia, and its impact on body weight, blood pressure, lipid profile and renal function.
Original languageEnglish
Pages (from-to)205-211
JournalClinica e Investigacion en Arteriosclerosis
Issue number4
Publication statusPublished - 1 Jan 2015


  • Cardiovascular risk
  • Dapagliflozin
  • Type 2 diabetes mellitus


Dive into the research topics of 'Dapagliflozin: Beyond glycemic control in the treatment of type 2 diabetes mellitus'. Together they form a unique fingerprint.

Cite this